Exelixis | EXEL - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Akebia Therapeutics USD 376.56M 12.41M 2025-12
Amgen USD 90.59B 445M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Bayer EUR 104.54B 331M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Cytokinetics USD 1.42B 12.02M 2025-12
Eisai JPY 1.49T 48.22B 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Genmab DKK 12.87B 5.85B 2025-12
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
MacroGenics USD 256.85M 13.92M 2025-12
Merck USD 129.55B 12.02B 2025-09
Moderna USD 12.34B 203M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sanofi EUR 126.81B 25.48B 2025-12
Takeda JPY 15.41T 938.47B 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Xencor USD 875.5M 6.68M 2025-12